Cannell & Spears LLC Has $4.03 Million Stake in IDEXX Laboratories, Inc. $IDXX

Cannell & Spears LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,176 shares of the company’s stock after selling 1,900 shares during the period. Cannell & Spears LLC’s holdings in IDEXX Laboratories were worth $4,026,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of IDEXX Laboratories by 37.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 133,891 shares of the company’s stock valued at $75,232,000 after buying an additional 36,281 shares during the last quarter. Dai ichi Life Insurance Company Ltd lifted its stake in shares of IDEXX Laboratories by 15.9% in the first quarter. Dai ichi Life Insurance Company Ltd now owns 3,645 shares of the company’s stock worth $2,048,000 after acquiring an additional 500 shares during the period. Renaissance Technologies LLC acquired a new position in shares of IDEXX Laboratories in the first quarter worth approximately $27,254,000. Public Employees Retirement System of Ohio boosted its holdings in IDEXX Laboratories by 1.2% in the first quarter. Public Employees Retirement System of Ohio now owns 29,652 shares of the company’s stock valued at $16,661,000 after acquiring an additional 347 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after acquiring an additional 288,471 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $544.32 on Friday. The firm has a market capitalization of $42.94 billion, a P/E ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55. The firm’s 50-day moving average price is $556.27 and its 200-day moving average price is $595.41. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business posted $2.91 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.